Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Current Treatment Options in Oncology|February 7, 2020
Neoadjuvant Immunotherapy for Locally Advanced MelanomaMeredith S Pelster, Rodabe N AmariaTherapeutic Advances in Medical Oncology|March 1, 2019
Combined targeted therapy and immunotherapy in melanoma: a review of the impact on the tumor microenvironment and outcomes of early clinical trialsMeredith S Pelster, Rodabe N AmariaThe Laryngoscope|May 11, 2019
Pembrolizumab-induced mucositis in a patient with recurrent hypopharynx squamous cell cancerMeredith S Pelster, Frank Mott, Jan LewinNPJ Precision Oncology|April 1, 2024
Post-therapy emergence of an NBN reversion mutation in a patient with pancreatic acinar cell carcinomaMeredith S Pelster, Ian M Silverman, Joseph D Schonhoft, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2023
Adagrasib in Advanced Solid Tumors Harboring a KRAS MutationTanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2020
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II StudyMeredith S Pelster, Stephen K Gruschkus, Roland Bassett, et al.The Oncologist|June 28, 2025
Phase 1 study of zavondemstat (TACH101), a first-in-class KDM4 inhibitor, in patients with advanced solid tumorsApostolia M Tsimberidou, Farshid Dayyani, David Sommerhalder, et al.The New England Journal of Medicine|December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12CRona Yaeger, Jared Weiss, Meredith S Pelster, et al.Cancer Discovery|April 8, 2024
Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal CancerRona Yaeger, Nataliya V Uboha, Meredith S Pelster, et al.Cancer|March 12, 2026
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancerGayle S Jameson, Denise J Roe, Erkut Borazanci, et al.Pageof 2